Skip to main content
. 2018 Apr 25;15(6):5231–5242. doi: 10.3892/etm.2018.6097

Figure 6.

Figure 6.

The effect of rhSLPI treatment on the myocardial infarct size of ex vivo murine hearts during myocardial I/R. (A) The study protocol for all experimental groups. The hearts of adult male C57BL/6 mice were perfused for 40 min with modified Krebs solution, or with modified Krebs solution containing 400 ng/ml rhSLPI or 1,000 ng/ml rhSLPI. Hearts were then subjected to 30 min global ischemia and 2 h reperfusion. (B) Infarct size was determined by TTC staining. Each bar graph represents the mean ± standard error of the mean (n=6). *P<0.05 vs. I/R alone. rhSLPI, recombinant human secretory leukocyte protease inhibitor; I/R, ischemia/reperfusion; LV, left ventricle.